Tamoxifen therapy

Longley, J. Donald; Ernst, D. Scott
September 1993
CMAJ: Canadian Medical Association Journal;9/15/1993, Vol. 149 Issue 6, p793
Academic Journal
No abstract available.


Related Articles

  • Tamoxifen Therapy for Retroperitoneal Fibrosis. Vaglio, Augusto; Greco, Paolo; Buzio, Carlo // Annals of Internal Medicine;4/18/2006, Vol. 144 Issue 8, p619 

    A letter to the editor is presented discussing tamoxifen therapy for retroperitoneal fibrosis.

  • How Is Tamoxifen's Action Subverted? Jordan, V. Craig // JNCI: Journal of the National Cancer Institute;01/19/2000, Vol. 92 Issue 2, p92 

    Discusses how to subvert the action of tamoxifen, an endocrine therapy of choice for breast cancer. Information on the therapy; Mechanism of action of the therapy.

  • Study clarifies tamoxifen's role in endometrial cancer risk. Lucas, Beverly D. // Patient Care;12/15/1999, Vol. 33 Issue 20, p15 

    Presents the findings of a study on the role of tamoxifen in determining endometrial cancer risks. High incidences of cancer risk for women administered with tamoxifen; Positive association of tamoxifen therapy with endometrial cancer; Correlation of body mass index with endometrial cancer.

  • Tamoxifen and Depression: More Evidence From the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study. Day, Richard; Ganz, Patricia A.; Costantino, Joseph P. // JNCI: Journal of the National Cancer Institute;11/7/2001, Vol. 93 Issue 21, p1615 

    Examines the effects of tamoxifen treatment for breast cancer prevention on women. Assessment of depression risk; Use of logistic regression; Evaluation of tamoxifen therapy.

  • Tamoxifen Therapy and Contralateral Breast Cancer. Sadovsky, Richard // American Family Physician;01/15/2000, Vol. 61 Issue 2, p518 

    Focuses on a study by R. O'Regan and associates which reviewed available data on tamoxifen therapy and contralateral breast cancer in women in an attempt to classify secondary neoplasms. Antiestrogen effects of tamoxifen in the breast; Reduced incidence of contralateral breast cancer with...

  • Five years of tamoxifen--or more? Peto, Richard // JNCI: Journal of the National Cancer Institute;12/18/96, Vol. 88 Issue 24, p1791 

    Editorial. Investigates the potentials of tamoxifen as the wonder drug for breast cancer. Statistics supporting the decline in breast cancer deaths upon the use of tamoxifen; Outcome of early clinical trials of tamoxifen and its effect on survival rate; Results of four trials of different...

  • Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph... Tormey, Douglass C.; Gray, Robert // JNCI: Journal of the National Cancer Institute;12/18/96, Vol. 88 Issue 24, p1828 

    Presents a study on the use of postchemotherapy adjuvant tamoxifen therapy among breast cancer patients. Efficacy of tamoxifen therapy; Demographic profile of patients; Proposal for the review of adjuvant tamoxifen therapy beyond five years in women with axillary lymph node-positive estrogen...

  • How long should tamoxifen therapy be administered? Diloreto, Stacy // Patient Care;7/15/2001, Vol. 35 Issue 13, p84 

    Discusses research on the benefit associated with tamoxifen therapy in women with lymph node-negative, estrogen receptor-positive breast cancer. Methods; Findings; Recommendation on the use of tamoxifen therapy.

  • Second cancers after adjuvant tamoxifen therapy for breast cancer. Curtis, Rochelle E.; Boice, John D. // JNCI: Journal of the National Cancer Institute;6/19/96, Vol. 88 Issue 12, p832 

    Presents a study on the use of adjuvant tamoxifen therapy on the treatment of breast cancer. Review of related literature; Method used in the selection of subjects for the study; Link between tamoxifen therapy and subsequent development of uterine corpus cancer.

  • Preliminary results from the Cancer Research Campaign trial evaluating tamoxifen duration in...  // JNCI: Journal of the National Cancer Institute;12/18/96, Vol. 88 Issue 24, p1834 

    Investigates the impact of two or three years of tamoxifen therapy on early breast cancer treatment. Profile of patients; Relapse intervals; Need for more research in the optimal duration of tamoxifen therapy.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics